ScienceFDA approves breast cancer drug aimed at tackling treatment resistance
Nature Biotechnology reports that the drug is linked with a test to detect ESR1 mutations in circulating tumor DNA.
TLDR
Nature Biotechnology reports FDA approval of a breast cancer drug linked with a test to detect ESR1 mutations in circulating tumor DNA. It describes the drug as part of a wave of new treatments developed to tackle resistance to therapies that target the estrogen receptor.
FDA approves breast cancer drug aimed at tackling treatment resistance
Nature Biotechnology reports that the drug is linked with a test to detect ESR1 mutations in circulating tumor DNA.
TLDR
Nature Biotechnology reports FDA approval of a breast cancer drug linked with a test to detect ESR1 mutations in circulating tumor DNA. It describes the drug as part of a wave of new treatments developed to tackle resistance to therapies that target the estrogen receptor.
